News

In late February 2026, a research study by Dr Nguyen Van Te (Head of Nuclear Medicine at FV Hospital) and his colleagues was officially published in the Journal of…

Investigators from multiple institutions conducted a study to assess the efficacy and safety of Renizgamglogene autogedemcel (reni-cel) in the treatment of…

AbstractAimsWhile cardiac magnetic resonance (CMR) provides prognostic value in transthyretin cardiac amyloidosis (ATTR-CA), current ATTR-CA staging relies on serum…

Brief SummaryTransthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-…

AbstractIntroductionTransthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized as a major cause of heart failure, due to improved awareness of red…

AbstractBackground Cardiac amyloidosis (CA) is frequently preceded by soft tissue infiltration, manifesting as orthopaedic "red flags" such as carpal tunnel…

Cardiovascular disease, the leading cause of deathTrusted Source globally, has not yet had an early-detection test — until now. On June 22, the Food and Drug…

AbstractInterpreting composite endpoints in cardiovascular drug development is a key challenge, particularly when events of different clinical relevance are…

Long-term treatment with diflunisal may help slow disease progression in people with hereditary transthyretin amyloidosis (hATTR), according to a Swedish real-world…

AbstractCardiac amyloidosis is a clinical condition characterized by deposition of amyloid fibrils in the myocardium, leading to increased left ventricular wall…